Charts

Gainers INVO Bioscience (NASDAQ:INVO) stock rose 275.0% to $2.85 during Wednesday's regular session. The market value of their ...

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has the potential to be the first FDA-approved hormone-free monthly intravaginal contraceptive for women SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of data from the postcoital test clinical study

Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript March 28, 2024 Daré Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.12. DARE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the conference call hosted […]

Q4 2023 Dare Bioscience Inc Earnings Call

Gainers Qilian Intl Hldg Gr (NASDAQ:QLI) shares increased by 73.2% to $1.1 during Thursday's after-market session. The company's market ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips DARE stock results show that Dare Bioscience beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. The post DARE Stock Earnings: Dare Bioscience Beats EPS, Beats Revenue for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Dare Bioscience (NASDAQ:DARE) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:00 AM. Here's what investors need to ...

Conference Call and Webcast Today at 4:30 p.m. ET2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial vaginosis under license agreement with commercial collaborator OrganonOvaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United StatesSildenafil Cream, 3.6% topical formulation of sildenafil being devel

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to ...

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 28, 2024, to review its financial results for the year ended December 31, 2023 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (international). The conference ID number for the call is 7156675

Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND clinical study, as well as improvement in multiple aspects of the sexual experience Continuing to work toward Phase 3 pivotal study There are no FDA-approved treatments for female sexual arousal disorder SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that additional data from the e

First LadyJill Bidenunveiled a significant milestone in the White House Initiative on Women’s Health Research by ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to get into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

There are no FDA-approved treatments for female sexual arousal disorderSAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the successful completion of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting advancement of Sildenafil Cream, 3.6% (Sil

SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors t

Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newbornsSAN DIEGO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $750,000 to fund activities related to bacteria-based live biotherapeutic product development. Daré previously received a grant

Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged TreatmentSAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has achieved technological proof of concept for DARE-LARC1 and the underlying innovative drug delivery platform designed to store and precisely deli

Daré Bioscience, Inc. ( NASDAQ:DARE ) is possibly approaching a major achievement in its business, so we would like to...

$5 million at closing and up to $7 million of additional committed fundingSAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has entered into a royalty-backed financing agreement that provides Daré with $5 million at closing and up to an additional $7 million through three tranches over time at Daré’s option. The financing structure entitles the investor to a percentage of the royalties and milestones to be

DarBioscience Inc(NASDAQ: DARE) announced topline results from the Phase 1 DARE-PDM1-001 study evaluating the ...

Gainers Aclarion (NASDAQ:ACON) shares rose 75.8% to $0.51 during Wednesday's pre-market session. The market value of their outstanding ...

Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary DysmenorrheaSAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1. DARE-PDM1 is an investigational product designed to deliver diclofenac, a nonsteroidal anti-infl

DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options Up to approximately $2 million in grant funding to support DARE-PTB1 Phase 1 human clinical study SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Develo

DarBioscience Inc(NASDAQ: DARE) announced that the FDA has cleared its investigational new drug (IND) application for ...

Gainers Dare Bioscience (NASDAQ:DARE) shares rose 31.1% to $0.46 during Thursday's pre-market session. The company's market cap stands ...

DARE-VVA1 has the potential to be the first therapeutic non-hormonal vaginal option for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) in women who cannot or should not take supplemental estrogenSAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for DARE-VVA

Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced commencement of the Company’s pivotal Phase 3 clinical study of Ovaprene, an investigational hormone-free monthly intravaginal contraceptive. The multi-center, single arm, non-comparative, pivotal Phase 3 clinical study of Ovaprene will evaluat

In this article, we will be navigating through adolescent fertility across the world while covering the 20 countries with the highest teenage pregnancy rates. If you wish to skip our detailed analysis, you can move directly to the 5 Countries with the Highest Teenage Pregnancy Rates. Adolescent Pregnancy Across the Globe Early pregnancy and motherhood […]

Partnership Aims to Advance Daré’s Reproductive Health Portfolio in a Timely and Capital Efficient MannerSAN DIEGO and MORRISVILLE, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Premier Research International, LLC, a global clinical research, product development, and consulting company, today announced that the companies extended their partnership agreement under which Premier Research will continue to provide on an exclu

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that an overview of the preliminary efficacy findings from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% (Sildenafil Cream) in women with female sexual arousal disorder (FSAD) will be presented at the upcoming

Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2023 Earnings Call Transcript November 9, 2023 Daré Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.1. Operator: Welcome to the conference hosted by Daré Bioscience to Review the Company’s Third Quarter Financial Results and to provide a General Business Update. This call is being recorded. My […]

Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Thursday, 2023-11-09. Here's what investors need to ...

Gainers Sientra (NASDAQ:SIEN) shares moved upwards by 9.2% to $1.77 during Monday's after-market session. The market value of their ...

Gainers Inventiva (NASDAQ:IVA) stock increased by 11.2% to $4.19 during Wednesday's after-market session. The company's market cap ...

On Monday, 27 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by ...

On Friday, 54 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: NovoCure ...

Dare Bioscience (NASDAQ:DARE) reported its Q1 earnings results on Thursday, May 11, 2023 at 08:00 AM. Here's what investors need to know ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Thursday, 2023-03-30. Here's what investors need to ...

DarBioscience Inc(NASDAQ: DARE) announcedtopline PK resultsfrom its Phase 1 / 2 trial of DARE-HRT1, an ...

HC Wainwright & Co. has decided to maintain its Buy rating of Dare Bioscience (NASDAQ:DARE) and raise its price target from $6.00 to ...

Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55 ...

Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them ...

From Evofem Biosciences Inc.’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc.’s (NASDAQ: DARE) ...

DarBioscience Inc(NASDAQ: DARE) announcedtopline efficacy resultsfrom its Phase 1/2 trial of ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Mersana, GSK Ink $1.36B ...

U.S. President Joe Biden said he had asked his administration to consider whether he has the authority to declare an abortion-related ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer, Africa CDC Strikes ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evofem Biosciences is in the spotlight following the overturning of Roe v. Wade. Here's why EVFM stock is a name to watch. The post EVFM Stock: Contraception Maker Evofem Biosciences Doubles After Roe Decision appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.

Three days after the U.S. Supreme Court struck down Roe v. Wade in one of the most potentially impactful rulings of the last century, a ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BridgeBio Inks Licensing ...

Dare Bioscience (NASDAQ:DARE) reported its Q1 earnings results on Thursday, May 12, 2022 at 06:00 AM. Here's what ...

Organon & Co(NYSE: OGN)will license global rightstoDarBioscience Inc's(NASDAQ: DARE) ...

Organon Enters into Global License Agreement to commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%)

Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth ...